Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
|Articles|September 16, 2008
- November15 2003
- Volume 10
- Issue 21
$ Out of the Gate
Advertisement
To achieve a satisfying retirement, today's doctors have to be good earners, good savers, and good investors—no easy trick. Luckily, earning good money might not pose such a problem. According to Private Practice Success (www.advisorypublication.com), here's a sampling of the average first-year salaries for various medical specialties:
Articles in this issue
about 18 years ago
Distinguish Tax Shelters from Tax Shamsabout 18 years ago
Modern-Day Robbery Steals Your Identityabout 18 years ago
Solve the Current Consolidation Debateabout 18 years ago
Physician Brings ER Attention to Politicsabout 18 years ago
Benjamin Rush, MD: Physician, Educator, Patriot & Writerabout 18 years ago
Help Your Kids Without Hurting Yourselfabout 18 years ago
Pick the Right Account for Your Savingsabout 18 years ago
Social Security: Back to Basicsabout 18 years ago
Commonsense Advice: Medical & Financialabout 18 years ago
Peter's PrinciplesAdvertisement
Related to this article
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Interim I CAN data show ravulizumab reduced proteinuria by 43.4% vs placebo at week 34, supporting its FDA accelerated approval in IgA nephropathy.
Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
4
Ravulizumab Receives FDA Accelerated Approval for IgA Nephropathy
5